What the FDA labels say about taking them together
Apalutamide and ritonavir
Ritonavir's FDA label of July 23, 2026 names apalutamide in its contraindications section; the apalutamide label PlainMeds reads does not name ritonavir. The ritonavir label: “Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors. …”
Check it at the source: the apalutamide FDA label on DailyMed (effective July 2, 2026, Janssen Products, LP); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the apalutamide label say about ritonavir?
Apalutamide's label (effective July 2, 2026) does not name ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ERLEADA), Janssen Products, LP, effective July 2, 2026 (SPL set d1cda4f7-cb33-46ea-b9ac-431f6452b1a5), via openFDA; the full label on DailyMed
What does the ritonavir label say about apalutamide?
Ritonavir label, contraindicationsNORVIR is contraindicated with drugs that are potent CYP3A inducers where significantly reduced ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )]. ○ Anticancer Agents: apalutamide ○ Herbal Products:
Ritonavir label, drug interactionsConcomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; Effect on Concentration of Ritonavir or Concomitant Drug: ↑ anticancer agents ↓ ritonavir #; Clinical Comment: Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors [see Contraindications () ]. Avoid co-administration of encorafenib or ivosidenib with NORVIR due to potential risk of serious adverse events such as QT interval prolongation. …
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Apalutamide | Ritonavir | |
|---|---|---|
| Labeled for | Prostate cancer | HIV |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once